Azelaic Acid Treatment For Rosacea and Melasma
This study evaluated the effectiveness and safety of topical azelaic acid (AA) for various dermatological conditions, including acne vulgaris, rosacea, hyperpigmentation/melasma, and skin aging. The researchers conducted a systematic review of randomized controlled trials (RCTs) with a minimum treatment duration of 6 weeks, searching databases like MEDLINE, Embase, CINAHL, and ClinicalTrials.gov up to December 2022. A total of 43 RCTs met the inclusion criteria.
In the context of rosacea, the meta-analyses from 20 studies demonstrated that azelaic acid significantly improved erythema severity, inflammatory lesion counts, overall improvement, and treatment success (achieving skin clarity) compared to a vehicle after 12 weeks of treatment. Furthermore, azelaic acid proved more effective than metronidazole 0.75% for improving erythema severity, overall improvement, and inflammatory lesion counts.
For acne, the analysis of 16 studies indicated that azelaic acid was more effective than a vehicle in enhancing global assessments and reducing acne severity. Notably, azelaic acid 20% also led to a significant reduction in lesions compared to erythromycin gel.
Within the realm of melasma, seven studies suggested that azelaic acid 20% was significantly superior to a vehicle in both severity and global improvement. Additionally, azelaic acid 20% yielded notably better results for global improvement compared to hydroquinone 2%.
Despite these promising findings, there were few significant differences in the occurrence of adverse events between AA and the comparison treatments. Notably, there were no eligible RCTs identified for evaluating the effects of azelaic acid on skin aging.
In conclusion, this study revealed that topical azelaic acid (AA) is more effective than a vehicle for treating rosacea, acne, and melasma. Moreover, comparisons between azelaic acid and other treatments often showed similar outcomes. In cases where these treatments are equivalent, azelaic acid may be considered a viable option for specific clinical situations. However, more RCT evidence is needed to assess the effectiveness of azelaic acid for addressing skin aging concerns.
Azelaic acid (AA) is a natural dicarboxylic acid found in grains like barley, wheat, and rye. It is also produced by Malasezzia furfur, a yeast residing on the skin, known to cause pityriasis (Tinea) versicolor, which affects melanin production and may result in hypopigmented areas. Additionally, azelaic acid possesses antimicrobial and anti-comedonal properties, along with various anti-inflammatory attributes. It inhibits tyrosinase, a key enzyme in melanin production, and suppresses the production of reactive oxygen species and proinflammatory cytokines, including IL-1, IL-6, and TNF-a.
Studies have revealed that azelaic acid can counteract inflammatory reactions induced by UV radiation, making it a valuable agent for conditions like rosacea, triggered or aggravated by sunlight exposure. Specifically, azelaic acid has been found to reduce the effects of ultraviolet B light on nuclear factor κB p65 subunit and p38 mitogen and stress-activated protein kinase. Moreover, azelaic acid enhances the activity of peroxisome proliferator-activated receptor γ (PPARγ), a crucial player in controlling inflammation.
Currently, AA is widely licensed and recommended worldwide for managing rosacea and acne vulgaris. It has also been employed for treating melasma, hyperpigmentation, and post-inflammatory hyperpigmentation (PIH), particularly in cases associated with acne and individuals with darker skin.
The aim of this systematic review is to provide an updated, high-quality evidence base assessing the efficacy and safety of topical azelaic acid for a range of dermatological concerns, including acne, rosacea, melasma, hyperpigmentation, and skin aging. This review serves to inform best practices and serves as a valuable reference for both patients and healthcare professionals in their decision-making processes.
This systematic review adhered to established principles outlined in the Cochrane handbook and the guidance provided by the Centre for Reviews and Dissemination. The review’s protocol was registered on PROSPERO (CRD42020220648).
The inclusion criteria encompassed randomized controlled trials (RCTs) with a treatment duration of at least 6 weeks. These trials compared topical azelaic acid (AA) in any dose or form with a vehicle, different azelaic acid doses, other medical treatments, or procedures. The study participants were healthy adolescents or adults aged 12 years or older. Outcomes of interest included the improvement in various dermatological conditions such as facial rosacea, acne, melasma, hyperpigmentation, and measures of anti-aging, including enhancements in photoaging, wrinkle reduction, and skin luminosity. Studies that assessed the combination of azelaic acid with other active medications in comparison to those medications alone were also included. Any treatment effectiveness scoring system was considered.
The review also examined adverse events data, encompassing local skin reactions like burning, pruritus, erythema, exfoliation, pain, dryness, discoloration, or irritation. Furthermore, serious adverse events, defined as reactions graded III or above by the study authors, were evaluated.
The search strategy for relevant trials involved searching various databases, including MEDLINE, PubMed, Embase, CINAHL, AMED, the TRIP database, Cochrane Library (CDSR and CENTRAL), NIHR Health Technology Assessment (NIHR HTA), and other NIHR journals, DARE, and the HTA database. Search terms encompassed keywords such as ‘azelaic acid,’ ‘Skinoren,’ ‘Finacea,’ ‘acne vulgaris,’ ‘hyperpigmentation,’ ‘melasma,’ ‘anti-aging,’ ‘photoaging,’ ‘wrinkles,’ and ‘rosacea.’
Two reviewers independently screened titles and abstracts from the search results, and full papers were retrieved for further assessment. The selected trials were critically appraised using the RoB 2 tool for RCTs, with disagreements resolved through discussion between the two reviewers.
Data synthesis in this review involved the collection of means and standard deviations for continuous outcomes, allowing for the estimation of study-specific and pooled mean differences, each accompanied by 95% confidence intervals (CIs). For dichotomous outcomes, numerators and denominators were collected, enabling the use of Mantel–Haenszel (M-H) risk ratios (RRs) and 95% CIs to summarize effect sizes.
Statistical heterogeneity was assessed through various means, including the χ2 test, the I2 statistic, and examination of random effects between study variance (τ2). Sensitivity analyses were conducted, which involved the exclusion of studies deemed to have a high risk of bias to assess the robustness of the results. Whenever possible, the GRADE system was employed to provide an assessment of the quality of evidence for each outcome.
In total, 43 randomized controlled trials (RCTs) met the eligibility criteria. Among these, 38 RCTs reported inter-individual comparisons, while five were intra-individual RCTs where each side of the face was randomized to receive different treatments. Among the reported outcomes, 20 RCTs assessed rosacea, 16 reported outcomes on acne, and seven reported outcomes on melasma. No RCTs were identified that specifically evaluated hyperpigmentation or measures of anti-aging.
Regarding the concentration of Azelaic Acid (AA), 20 RCTs assessed AA 20% in gel or cream form, 19 assessed AA 15% in gel or foam form, one evaluated AA 5% in gel form, and two trials did not report the dose of azelaic acid used. The studies were conducted in various countries, with the USA, Iran, and the UK being the primary locations. Some studies were multinational in scope. Of the study populations, 29 trials were conducted in adults, 11 in both adolescents and adults, and three did not report the age range of the participants. Additionally, six studies provided details on the Fitzpatrick skin type.
Assessing the risk of bias, 37 out of the 43 RCTs were found to have ‘some concerns’ in at least one aspect, including the randomization process, deviations from intended interventions, missing outcome data, measurement of outcomes, or selection of reported results. Six RCTs were considered to have a high risk of bias due to factors such as inadequate allocation concealment, substantial participant withdrawals leading to per protocol analysis, or lack of blinding. Notably, no studies were classified as having a low risk of bias.
The study included 20 randomized controlled trials (RCTs) focusing on rosacea, 16 RCTs related to acne, and 7 RCTs pertaining to melasma. These trials involved various treatment comparisons, including azelaic acid (AA) versus different control treatments, as well as comparisons of treatment frequencies.
- Study participants were mainly adults aged 18–83, with an average age of 49.7, predominantly female (75.4%), and primarily of white ethnicity (89.2%).
- The rosacea study outcomes were assessed using parameters like improved erythema (redness of the skin) severity, lesion counts, overall improvement, and treatment success.
- A meta-analysis showed that azelaic acid, specifically azelaic acid 15%, was more effective than a vehicle in improving erythema severity. The analysis found a 51% mean improvement in patients using azelaic acid compared to a 36% improvement in the control group.
- There was some heterogeneity statistically in the studies.
- The quality of study findings was considered to be moderate.
Inflammatory Lesion Counts:
- There was consistent, moderate-quality evidence that both azelaic acid 15% and 20% were more effective than the vehicle in reducing inflammatory lesion counts (papules and pustules).
- The mean reduction in inflammatory lesion count was 63% with azelaic acid and 48% with the vehicle.
- Low-dose azelaic acid (5%) combined with clindamycin was also more effective than clindamycin alone.
- No significant differences were observed in comparisons between azelaic acid and other treatments in most cases.
- Azelaic acid (15% or 20%) was found to be better than a vehicle in terms of overall improvement in rosacea. Those using azelaic acid were 1.5 times more likely to experience complete remission, marked improvement, or ‘good to excellent’ ratings compared to those receiving a vehicle.
- Some heterogeneity was noted statistically.
- No significant differences were observed in some comparisons, such as treatment frequency or between azelaic acid and specific treatments.
- High-quality evidence indicated that azelaic acid 15% was more effective than the vehicle in achieving ‘skin clear or nearly clear’ results.
- No studies were considered to have a high risk of bias.
Maintenance Therapy in Rosacea:
- A study assessed the efficacy of azelaic acid 15% as a maintenance therapy in rosacea. Initially, a significant proportion of participants experienced improvement, and this was maintained during the second phase of the study, with azelaic acid 15% gel outperforming the vehicle.
- Sixteen RCTs examined ten different treatment comparisons for acne vulgaris. Participants were aged 11–50, predominantly female (53%), and had mild to moderate acne.
- Common outcomes included reduction in lesion counts, global improvement, and reduction in severity.
Reduction in Lesion Counts:
- Some evidence suggested that azelaic acid 20% was more effective than the vehicle in reducing lesions.
- Low-dose azelaic acid (5%) combined with clindamycin outperformed clindamycin alone.
- Azelaic acid 20% was better than erythromycin gel 2%, but combined benzoyl peroxide 3% and clindamycin 1% gel performed better than AA 20%.
- In some comparisons, no significant differences were observed.
- AA 20% was more effective than a vehicle and benzoyl peroxide 5% in terms of overall improvement.
- No significant differences were observed between azelaic acid and other treatments in most cases.
Reduction in Severity:
- Some evidence showed that azelaic acid 20% was better than the vehicle, with a 3.06 times more effective result in terms of the Acne Severity Index (ASI) scores.
- Low-dose AA (5%) combined with clindamycin gel 2% outperformed clindamycin alone.
- Seven RCTs examined four different treatment comparisons for melasma. Participants had Fitzpatrick skin types II–V and were mainly of Asian/Middle Eastern, Hispanic, or Black ethnicity.
- The reported outcomes included melasma severity, global improvement, and lesion size reduction.
- Results varied depending on the assessment method.
- AA 20% was more effective than the vehicle, and AA 20% was better than hydroquinone 2% in terms of reducing melasma severity.
- Topical tranexamic acid 3% was more effective than AA 20%.
- No significant differences were observed in some comparisons.
- AA 20% was more effective than the vehicle.
- AA 20% was more effective than hydroquinone 2%, but not hydroquinone 4%.
- No significant differences were observed in one comparison.
Lesion Size Reduction:
- No significant differences were observed in this regard.
Skin Aging Studies:
- No studies on the use of azelaic acid in skin aging were included in the review.
- Serious adverse events were rare, with most studies reporting no serious adverse events.
- Commonly reported adverse events included itching, pain, dryness, and irritation. These side effects were more pronounced in the AA groups compared to the control groups in some cases. However, very few significant differences were observed between azelaic acid and the comparison treatments in terms of adverse events.
This systematic review highlights the effectiveness of azelaic acid (AA) in the treatment of rosacea, acne, and melasma. When compared to vehicles (placebo), Azelaic acid consistently showed superior results in managing these skin conditions. In cases where azelaic acid demonstrated similar efficacy to other active treatments, it can still be a valuable option, especially for patients who cannot tolerate equivalent treatments or where the safety of other treatments during pregnancy is a concern.
It’s worth noting that, while there were few notable differences in commonly reported adverse events between azelaic acid and comparators, potential side effects, such as itching and pain, should be considered by clinicians.
However, the review also underscores the need for further research to explore the role of azelaic acid in anti-aging. Additional studies in this area could provide valuable insights into the potential benefits of azelaic acid in addressing age-related skin concerns.
Oncology Related Tools
- Prognostic Scoring for Myelofibrosis
- Opioid Conversion Calculator
- Updated Advanced Opioid Conversion Calculator
- Nonsteroidal anti-inflammatory drugs (NSAID) Selection Tool
- Absolute Neutrophil Count Calculator
- Body Surface Area (BSA) Multi-Calc
- Carboplatin AUC Calculator
- Carboplatin AUC – Updated Version
- Urinary Indices, Renal Failure Index (RFI) and Fractional Excretion of Sodium (FE-NA)
- Creatinine Clearance (CRCL) – Standard Calculator
- Creatinine Clearance Multi-Calc – All of the latest research
- Patient Controlled Analgesia (PCA) Settings
- Intravenous Antineoplastic Agents – Administration Guidelines
- Therapeutic Drug Levels
- Beers Criteria for potentially inappropriate medications
- Allergic response? 12-step desensitization protocol
- Protein requirements calculator
- Basal Metabolic Rate (BMR) Multi-calc (Estimate caloric requirements)
- Irritable Bowel Syndrome Treatment Options
- Common Anti-emetics
- Fall Assessment – Berg Balance Scale
- Topical Steroids Potency Selection Tool
- Rheumatoid Arthritis Work Limitation Factors
- Secukinumab Therapy In Psoriasis
- Lung Cancer Patients And Pulmonary Embolism Risk Factors
- Squamous Cell Carcinoma And Immunosuppression Risks
- Necrotizing Fasciitis Treatment And Bacterial Isolates Mortality Risk
- Acellular Dermal Matrix (ADM) For Burn And Trauma Wounds
- Visceral Adiposity And Heart Failure Risk
- Psoriasis Risk In Children With High BMI
- Traumatic Scalp Defects: Case Studies And Treatment Approaches
- Perforator Flaps For Patellar Defects
- GERD And Risk Factors Of Age And Obesity
- Cataract Repair: 20-Year Outcomes In Diabetic Patients
- Spitz Lesions: Clinical Outcomes
- Obesity Treatment With Tirzepatide And Semaglutide
- Hydroxyurea: Pediatric Use In Sickle Cell Anemia
- AKI In Alcohol-Related Hepatitis
- Biologic Therapy Tapering In Inflammatory Arthritis
- Rheumatoid Arthritis: Monitoring Disease With Neutrophil-To-Monocyte Ratio
- Cefuroxime Prophylaxis For Cataract Postoperative Endophthalmitis
- HIV Treatment And Long-Acting Therapy Preferences
- Idiopathic Parkinson’s Tremors: Treatment Options
- Ganaxolone Treatment For Refractory Epilepsy
- Bipolar Disorder And The Impact Of Insulin Sensitivity
- Blue Light Therapy For Melasma Patients
- Insulin Sensitivity In The Brain And Periphery
- Cabozantinib Therapy In Hepatocellular Carcinoma
- Obese Children And Related Skin Conditions
- PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma
- Skin Lightening: Topical Approaches To Treatment
- PPE And Skin Related Reactions
- Encapsulated Papillary Carcinoma Membrane Characteristics
- Ibrutinib Treatment In Waldenström Macroglobulinemia
- Eyelid Carcinoma (SGC): A Tool To Predict Recurrence
- Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications
- Cognitive Behavioral Therapy In Patients With Insomnia And Chronic Fatigue
- Chemotherapy-Induced Thrombocytopenia In Nasopharyngeal Carcinoma
- Endocrine Therapy Outcomes In Senior Breast Cancer Patients
- Hepatocellular Treatment Outcomes: The Influence Of Butyrate Producers
- Non-Invasive Breast Carcinoma Treatment Outcomes
- Control Of Allergic Rhinitis And Asthma Test: A COSMIN Analysis
- Pilonidal Sinus Disease And Carcinoma Prevalence
- Sintilimab And Docetaxel Treatment Comparison In Advanced Lung Cancer
- Tislelizumab Treatment And Quality Of Life In Lung Cancer Patients
- Ciclopirox Hydrolacquer Therapy For Adult Onychomycosis
- Allergic Rhinitis And Genetic Risk Factors
- Serum Potassium Levels And Mortality Risk In CKD
- Postoperative Delirium In The NICU: Hormonal Risk Factors
- Onychomycosis And Diabetic Foot Syndrome
- Childhood BMI And Allergies: A Comprehensive Review
- Pediatric Onychomycosis Prevalence: A Systemic Review
- Hormone Disturbances In Migraine Disorder: A Meta-Analysis
- IGF-1 Levels In Pediatric Low-Level Gliomas
- Visual Field Defects In Patients With Pituitary Tumors
- Chronic Spontaneous Urticaria: Studying Age-Specific Therapies
- Levothyroxine Treatment In Patients With Thyroid Cancer
- Ocular Surgery In Infants And Post-Op Eye Drop Risks
- Cancer Care: Gender Bias In Decision-Making
- Respiratory Syncytial Virus Infection: A Tool For Assessing Clinical Severity
- Gynecologic Cancer Survivors: A Study Of Lifestyle Factors
- Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk
- Antithyroid Drug Therapy And Cardiovascular Morbidity
- Eosinophilic Dermatosis In Hematological Malignancy (EDHM): Case Study Reports
- Uterine Leiomyosarcoma: A-Meta Analysis Of Systemic Therapy Effectiveness
- Off-Label Medication Use In Oncology
- Monocytosis And Patient Risk Of Malignancy And Mortality
- Bedside Pediatric Early Warning System: A Validation Study
- Chronic Hyponatremia In Heart Failure
- Massage Therapy For Oncology Patient Pain
- Eyelid Rhabdomyosarcoma Survival In Children’s Oncology
- Injured Athletes: A Meta-Analysis Comparing Topical And Oral Analgesic Efficacy
- Acute Myeloid Leukemia And Diverse Patient Survival Outcomes
- Sarcopenia And Chronic Kidney Disease
- Childhood Obesity: Targeted Dietary Interventions
- Supragastric Belching And Acid Reflux Severity
- Diabetic Peripheral Neuropathy Diagnosis Using Nerve Ultrasonography
- IBD: A Link To Cancer And Infection
- Renal Transplant Risks With Prostate Cancer
- COPD Risk With Diabetes And Pre-Diabetes
- Urothelial Carcinoma – Uretal And Renal Pelvic Tumors
- Merkel Cell Carcinoma: A Case Of Metastasis To The Tonsils
- Infant Formula Protein Content And Childhood Obesity
- Maternal Migraines And Associated Pediatric Cancers
- Pediatric Neuroblastoma Diagnosis Using Urinary Catecholamine Metabolites
- Finerenone Therapy In CKD And Type 2 Diabetes
- Binge Eating Habits And Diabetic Implications
- Pain Intensity In Idiopathic Inflammatory Myopathies And Rheumatic Diseases
- Melanoma Diagnosis Without Biopsy
- Pediatric Opioids And Pain Control In Fractures
- Daikenchuto Treatment For Chronic Constipation
- Prenatal Gingivitis Prevalence In A Clinical Trial Exploring Oral Hygiene Education
- Autistic Adults: A Study On Cognitive Therapy Experiences
- The Impact Of Long-Term Opioid Treatment On Endocrine Parameters
- Skeletal Muscle Index And Ovarian Cancer Prognosis: A Meta-Analysis
- Diabetes Mellitus During The Pandemic
- Carfilzomib Therapy In Pediatric Acute Lymphoblastic Leukemia
- Golimumab Compliance In Long-Term Arthritis Treatment
- Medullary Thyroid Cancer And Vocal Cord Paralysis
- Primary Adenocarcinoma Of The Orbit: A Case Study
- Survival Trends: Pancreatic Cancer in the USA
- Nusinersen Therapy For Pediatric Spinal Muscular Atrophy
- Pediatric Liver Transplantation: A New Biological Abdominal Wall
- Influenza Surveillance: A Review Of Data Sources
- Remission of Renal Cell Carcinoma With Brain Metastases: A Case Study
- Dry Eye Disease And Dehydration
- Macular Edema Therapy Using Dexamethasone Nanoparticle Suspension
- Colorectal Cancer Screening For Older Adults
- Satiation And Satiety: An Overview And Clinical Calculator
- Cholesterol Screening To Aid In Glaucoma Detection
- Hearing Screening After Chemotherapy: A Study On Childhood Cancer Survivors
- Olfactory Dysfunction and Screening For Depression: A QOL Study
- Cancer Diagnosis And Mental Health
- Mental Health Screening In Psoriatic Arthritis Patients
- Prostate Cancer: A New Biopsy Risk Calculator Using MRI
- Mental Health Study in Cancer Survivors
- Mental Health Screening In The Community
- Bone Mineral Density Screening Combined With Mammography
- Bone Mineral Density In Type 1 Diabetes Mellitus
- Cochlear Implants and Vestibular Screening
- Aprocitentan In Resistant Hypertension
- Predicting Cardiovascular Disease With Body Mass Index
- Obesity Screening To Predict Hot Flashes
- Hypertension Screening For Cardiovascular Health
- Dental Screening For Cardiovascular Disease Risk
- Blood Pressure and CVD Risk Reduction
- Lifestyle Changes For Hypoglycemia Prevention
- Ovarian Adenocarcinoma With Glaucoma: A Case Report
- Community Hypertension and Atherosclerosis Risk
- Thyroid Malignancy and Serum Calcitonin
- Rare Schwannoma In Lateral Nasal Wall
- Pyrotinib Therapy In HER2+ Breast Cancer
- Osteopenia Predicts Outcomes in Pancreatic Cancer
- Outcomes of Physical Exercise Regimens in Advanced Cancer
- Penile Squamous Cell Carcinoma And HPV
- Radiation Therapy And VTE Risk
- Pseudouveitis With Pancreatic Carcinoma: A Case Study
- Cancer Prevention In Rural Communities
- Skeletal Muscle Mass and Cancer Patient Quality of Life: A Meta-Analysis
- Incidence of Secondary Cancers After CIRT VS RT
- Filanesib Combination Therapy in Multiple Myeloma
- Pediatric Leukemia Patients Utilizing Levofloxacin
- Breast Cancer And An Analysis Of Cardiovascular Events
- Monotherapy Or Chemotherapy Adjunct: Pembrolizumab in Advanced NSCLC
- Advanced Gastric Cancer: Prognosis with Nivolumab Monotherapy
- Sinonasal B‐Cell Lymphomas A Cohort Study On Progression And Recurrence
- Platinum Resistant Recurrent Ovarian Cancer Treatment+/-Bevacizumab
- Metastatic Melanoma and Follow-Up MRI Scans
- Isatuximab Treatment in Refractory T-Acute Lymphoblastic Leukemia
- Ocular Melanoma and Treatment with Metformin
- Gastric Neuroendocrine Neoplasms
- Lung Cancer with Brain Metastasis After Late-Onset Bipolar Disorder: Case Report
- Anlotinib with Camrelizumab in Lung Cancer Treatment
- Sebaceous Carcinoma Treatment Outcomes: A Multicenter Study
- Diffuse-Type Tenosynovial Giant Cell Tumors: Treatment and Progression
- Lung Spindle Cell Carcinoma Responsive to Pembrolizumab: A Rare Case Report
- DNA Methylation Profiling in Sarcoma Classification
- Breast Tomosynthesis Simulator For Virtual Clinical Trials
- Renal Cell Carcinoma-Prognosis Via Albumin Levels
- Diagnostic Error Causing Cases of Cytopenia
- Hodgkin’s Lymphoma: A Case Study With Nystagmus and Diplopia
- Brugada Syndrome Treated with Lenalidomide: A Case Study
- Koolen-de Vries Case Study
- Suicidal Ideation and Somatic Treatments
- Study on Pavlovian Fear Conditioning and Fear Reversal in OCD
- Anxiety Scales in Lewy Body Disease
- Inoperable Locally Advanced Non-Small Cell Lung Cancer: Survival Rates of Endostar, CCRT
- Physician Practice Management and Private Equity
- Physician Spending And Its Association With Patient Outcomes
- Physician Burnout: Causes and Prevention
- LEAP-MS: Adaptations for Advanced Stages
- MS: Exercise Impacts on MRI
- The Role of Preretirement Job Complexity in Cognitive Performance
- Extrapontine Myelinolysis and PTA in Pregnancy
- Verbal Communication and Masks
- Sugammadex Versus Neostigmine in Thyroidectomy
- SGLT Inhibitors on Weight and Lipid Metabolism in Diabetes
- Saxagliptin: Obese Patients with Impaired Glucose Tolerance
- Levothyroxine Therapy and Depression
- Grave’s Disease and Risk of Systemic Lupus Erythematosus
- Benign Thyroid Removal and Patient Satisfaction
- MF- Biology, Management, and a Case Study of Ocular Manifestation
- Quality Of Life In Adolescent Cancer Survivors
- Cancer Opioid Risk Score
- Oncology-Specific Opioid Risk Calculator In Cancer Survivors
- 3D MRI for Non-invasive Ocular Proton Therapy of Uveal Melanomas
- Sexual Dysfunction in Prostate Cancer Patients
- 3-Day Surprise Question To Predict Survival Rates in Advanced Cancer Patients